On Jan. 25, 2021, the NIH announced that in large clinical trial conducted worldwide, full dose anti-coagulation (blood thinner) treatments given to moderately ill patients hospitalized for COVID-19 reduced the requirement of vital organ supportﾗsuch as the need for ventilation.

A trend in possible reduction of mortality was also observed and was being further studied. With large numbers of COVID-19 patients requiring hospitalization, these outcomes could also help reduce the overload on intensive care units around the world.